Description
A pyrimidine 2'-deoxyribonucleoside that is the L-enantiomer of thymine. A synthetic thymidine nucleoside analogue with activity against HBV DNA polymerase.
Chemical properties
| Chemical formula | Net charge | Average mass |
|---|---|---|
| C10H14N2O5 | 0 | 242.22860 |
Nomenclature
| IUPAC | SMILES | InChI | InChIKey | Synonyms |
|---|---|---|---|---|
| 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione | Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O | InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1 | IQFYYKKMVGJFEH-CSMHCCOUSA-N |
|
Citations
- Brown, JA, et al. 2011. Presteady state kinetic investigation of the incorporation of anti-hepatitis B nucleotide analogues catalyzed by noncanonical human DNA polymerases. Chemical Research in Toxicology. 25(1).
- Dang, S, et al. 2011. Rhabdomyolysis in a 48-year-old man with hepatitis B-induced cirrhosis. The American Journal of the Medical Sciences. 342(1).
- Gane, EJ, et al. 2011. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver International : Official Journal of the International Association For the Study of the Liver. 31(5).
- Han, GR, et al. 2011. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. Journal of Hepatology. 55(6).
- Huang, J, et al. 2011. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology. 19(3).
- Nan, XP, et al. 2012. Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. Viral Immunology. 25(1).
- Safadi, R, et al. 2010. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine. Liver International : Official Journal of the International Association For the Study of the Liver. 31(5).
- Seto, WK, et al. 2010. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. Journal of Hepatology. 55(3).
- Shi, TD, et al. 2011. Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. Clinical and Experimental Medicine. 12(2).
- Singal, AK, et al. 2012. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Alimentary Pharmacology & Therapeutics. 35(6).
- Tsai, MC, et al. 2011. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. The Journal of Antimicrobial Chemotherapy. 67(3).
- Wiens, A, et al. 2011. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B. The Brazilian Journal of Infectious Diseases : An Official Publication of the Brazilian Society of Infectious Diseases. 15(3).
- Zou, XJ, et al. 2011. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. Journal of Viral Hepatitis. 18(12).